Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

NCT04416633 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-11-08

Study results available
· View outcomes & findings →

Summary

A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)

Conditions

  • Unresectable Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Durvalumab

500-mg/120-mg IV

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2023-10-27
Completion
2023-10-27

Countries

  • India

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04416633 on ClinicalTrials.gov